5月29日，博晖创新今日收盘5.93元，上涨2.07%，最新市净率3.52，总市值48.44亿元。 最新一期业绩显示，2025年一季报，公司实现营业收入2.02亿元，同比-23.05%；净利润-4054437.18 元，同比-120.41%，销售毛利率38.37%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)5博晖创新-330.17523.933.5248.44亿行业平均 49.6447.924.61106.85亿行业中值36.3637.152.4549.28亿1天益医疗-1776.29-3042.591.9022.64亿2澳华内 镜-644.66323.335.1667.94亿3诺唯赞-407.58-482.062.2487.22亿4爱朋医疗-359.62273.204.3329.51亿6奥精 医疗-139.08-203.851.8325.81亿7硕世生物-137.56-2010.081.2340.24亿8睿昂基因-102.37-84.041.4513.25亿9 康泰医学-89.13-75.303.1858.66亿10中红医疗-72.45-57.790.9250.35亿11华大智造-55.85- ...

Group 1 - The core business of Beijing Bohui Innovation Biotechnology Group Co., Ltd. is the research, production, and sales of in vitro diagnostic products, including testing instruments, software, reagents, calibration products, quality control products, and national standard substances [1] - As of the first quarter of 2025, the company reported a revenue of 202 million yuan, a year-on-year decrease of 23.05%, and a net profit of -4.05 million yuan, a year-on-year decrease of 120.41%, with a gross profit margin of 38.37% [1] - The latest closing price of Bohui Innovation was 5.78 yuan, down 2.69%, with a price-to-book ratio of 3.43 and a total market value of 4.722 billion yuan [1] Group 2 - The company has one institutional holder with a total holding of 4.1405 million shares, valued at 2.3 million yuan [1] - The company's PE (TTM) is -321.82, while the industry average PE (TTM) is 48.71, indicating a significant underperformance compared to the industry [2] - The industry median price-to-book ratio is 2.40, while Bohui Innovation's price-to-book ratio is 3.43, suggesting a higher valuation relative to its peers [2]

Company Overview - Beijing Bohui Innovation Biotechnology Group Co., Ltd. specializes in the research, production, and sales of in vitro diagnostic products, including testing instruments, software, reagents, calibration materials, quality control products, and national standard substances [1]. Financial Performance - For Q1 2025, the company reported revenue of 202 million yuan, a year-on-year decrease of 23.05% [1]. - The net profit for the same period was -4,054,437.18 yuan, reflecting a year-on-year decline of 120.41% [1]. - The gross profit margin stood at 38.37% [1]. Market Metrics - As of May 20, the company's stock closed at 5.94 yuan, up 1.54%, with a latest price-to-book ratio of 3.53, marking a 15-day low [1]. - The total market capitalization is 4.852 billion yuan [1]. - Over the past five days, the main capital flow showed a net inflow of 618,100 yuan, although the overall trend was a net outflow of 20.5314 million yuan [1]. Industry Comparison - The company's price-to-earnings (P/E) ratio (TTM) is -330.72, while the industry average is 49.51 [2]. - The company's price-to-earnings (static) ratio is 524.81, compared to the industry average of 47.73 [2]. - The industry median price-to-book ratio is 2.51, while Bohui Innovation's is 3.53 [2].

当前人工智能发展势头迅猛，人们对于AI工具的应用也越来越多元。不少高校学生在撰写学术论文或 者进行毕业设计时也会使用AI技术。相比翻阅厚重的书籍资料或者利用互联网搜索引擎查找资料，借 助AI写论文，更加方便、实用，却也引发了更多担忧和相关的讨论。 总台中国之声曾经关注过复旦大学发布首个国内高校"AI禁令"，今年以来，不少高校纷纷推出新的政策 为AI"立规矩"，规范学生使用生成式人工智能的行为。学术写作中使用AI的边界如何界定？高校如何引 导学生合理使用？ 越来越多高校学生开始尝试用AI生成学术论文。这看起来为撰写论文提供了便捷途径，但过度依赖 AI，显然背离了学术研究和论文写作的初衷。 去年保研武汉大学的小蔡告诉总台中国之声，此前他在写本科毕业论文时，曾借助过AI。 小蔡：毕业论文在做课题研究的过程中需要学习新知识，有很多之前不了解的东西，可以把我们不懂的 问题直接输入进去，让AI给我做一个比较系统全面的介绍，也让我们对技术、背景有更多的认识，节 省时间、提高效率。 小蔡坦言，AI只是辅助工具，自己在论文的写作层面并不会依赖它。 小蔡：在后面的写作环节，很多高校确实讨论过这个问题，我本人不会直接用到自己的写作 ...

投资者关系活动记录表 编号：2025-002 | | ☐特定对象调研 ☐分析师会议 | | --- | --- | | | ☐媒体采访 业绩说明会 | | 投资者关系活动类别 | ☐新闻发布会 ☐路演活动 | | | ☐现场参观 | | | ☐其他（请文字说明其他活动内容） | | 参与单位名称及人员 | 线上参与公司2024年年度业绩说明会的全体投资者 | | 姓名 | | | 时间 | 2025年04月09日 15:00-17:00 | | 地点 | 价值在线（https://www.ir-online.cn/）网络互动 | | | 董事长、总经理 ZHONGBIN SUN | | | 独立董事 孙进山 | | 上市公司接待人员姓名 | 董事会秘书 朱慧芬 | | | 保荐代表人 范璐 | | | 1、2024年净利润同比下滑88.38%，公司计划通过哪 | | | 些措施改善盈利能力？ | | | 您好，感谢您的关注！公司2025年将开源节流、降本 | | 投资者关系活动主要 | 增效，提高经营利润健康水平。具体来看，跨境电商零售 | | 内容介绍 | 业务方面，将精细化运作海外仓业务，依托数据分析提 ...